Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAWNASDAQ:CALANASDAQ:NTHINASDAQ:VSAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.01$0.01$0.06▼$0.33N/AN/A34,287 shsN/ACALACalithera Biosciences$0.00$0.00▼$0.05N/A-2.5616,027 shsN/ANTHINeonc Technologies$4.26-10.5%$6.52$4.11▼$25.00N/AN/A65,138 shs17,554 shsVSARVersartis$1.19$1.19$1.14▼$2.76N/AN/A479,436 shs349,963 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%-24.76%-52.61%-72.30%CALACalithera Biosciences0.00%-95.00%-83.33%0.00%-99.20%NTHINeonc Technologies0.00%-24.06%-41.88%+425,999,900.00%+425,999,900.00%VSARVersartis0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera Biosciences0.5916 of 5 stars0.01.00.04.50.60.00.0NTHINeonc TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AVSARVersartisN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/ANTHINeonc Technologies 0.00N/AN/AN/AVSARVersartis 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/ANTHINeonc Technologies$79.99KN/AN/AN/AN/AN/AVSARVersartisN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00N/AN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/A0.00∞N/AN/AN/AN/AN/AVSARVersartisN/AN/A0.00∞N/AN/AN/AN/AN/ALatest VSAR, AEHAW, CALA, and NTHI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025NTHINeonc TechnologiesN/A-$2.10N/A-$2.10N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ANTHINeonc TechnologiesN/AN/AN/AN/AN/AVSARVersartisN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera BiosciencesN/ANTHINeonc TechnologiesN/AVSARVersartis38.52%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/ACALACalithera Biosciences6.60%NTHINeonc TechnologiesN/AVSARVersartis10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableCALACalithera Biosciences604.87 million4.55 millionNot OptionableNTHINeonc Technologies8N/AN/AN/AVSARVersartisN/AN/AN/AOptionableVSAR, AEHAW, CALA, and NTHI HeadlinesRecent News About These CompaniesISRO Announces Launch Date For Venus Orbiter Mission | All About Shukrayaan-1October 3, 2024 | outlookindia.comGrowth hormone could be filed without further trials, says OPKOSeptember 24, 2024 | pharmaphorum.com16 Biopharma Companies Besides Medivation That Are Attractive TargetsJuly 21, 2023 | thestreet.comJohn Newman's Stock Ratings - BenzingaMay 11, 2023 | news.google.comGlobal Human Growth Hormone Market Assessment 2023-2030 ... - Cottonwood Holladay JournalMay 11, 2023 | news.google.comHDAX THERAPEUTICS ANNOUNCES APPOINTMENT OF DRS ... - InvestorsObserverApril 11, 2023 | news.google.comHuman Growth Hormones Deficiency (Ghd) Drug Market 2023 with Growth Overview, Developments in Manufacturing Te - openPRMarch 28, 2023 | news.google.comHuman Growth Hormones Deficiency (Ghd) Drug Market is booming ... - Trending in PakistanFebruary 15, 2023 | news.google.comInjured snowmobiler rescued from Enderby backcountryJanuary 24, 2023 | globalnews.caSecret CSO: Todd Dekkinga, Zluri - IDG ConnectJanuary 12, 2023 | news.google.comDon't Tell Anyone: Insiders Are Buying These Stocks Like CrazyDecember 28, 2022 | thestreet.comElixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board ... - GlobeNewswireDecember 21, 2022 | news.google.comGlobal Human Growth Hormones Deficiency (Ghd) Drug Market Upcoming Innovations, Companies, and Forec - PharmiWeb.comNovember 18, 2022 | news.google.comScrut Automation Hires Todd Dekkinga as Its Chief Information Security Officer - Press Trust of India - archive.ptinews.comOctober 21, 2022 | news.google.comTodd Dekkinga named Chief Information Security Officer at Zluri - Security MagazineOctober 12, 2022 | securitymagazine.comZluri Hires Todd Dekkinga as Chief Information Security Officer - PR WebOctober 11, 2022 | prweb.comZluri Hires Todd Dekkinga as Chief Information Security Officer - Yahoo FinanceOctober 11, 2022 | finance.yahoo.comPhase 3 flop puts Versartis on life support - FierceBiotechOctober 9, 2022 | fiercebiotech.comHuman Growth Hormones Deficiency (GHD) Drugs Market Prospects & Upcoming s and Opportunities Analyzed for Coming Years – This Is Ardee - This Is ArdeeJuly 25, 2022 | thisisardee.ieHuman Growth Hormones Deficiency (GHD) Drugs Market Revenue Growth, Key Players | Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc. – Designer Women - Designer WomenJune 29, 2022 | designerwomen.co.ukNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVSAR, AEHAW, CALA, and NTHI Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.01 0.00 (0.00%) As of 06/20/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Calithera Biosciences NASDAQ:CALACalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Neonc Technologies NASDAQ:NTHI$4.26 -0.50 (-10.50%) As of 06/20/2025 04:00 PM EasternNeonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.Versartis NASDAQ:VSARAravive, Inc. operates as a clinical stage biotechnology company. The firm engages in the development of new therapies that target important survival pathways for both advanced solid tumors as well as hematologic malignancies. Its product candidate, Aravive-S6, is a soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL which also promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The company was founded on December 10, 2008 and is headquartered in Houston, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
